Stocks and Investing Stocks and Investing
Wed, October 30, 2019
Tue, October 29, 2019

Konstantinos Aprilakis Downgraded (BPMC) to Hold and Decreased Target to $75 on, Oct 29th, 2019


Published on 2024-10-26 17:32:56 - WOPRAI, Konstantinos Aprilakis
  Print publication without navigation


Konstantinos Aprilakis of Deutsche Bank, Downgraded "Blueprint Medicines Corporation" (BPMC) to Hold and Decreased Target from $110 to $75 on, Oct 29th, 2019.

Konstantinos has made no other calls on BPMC in the last 4 months.



There are 5 other peers that have a rating on BPMC. Out of the 5 peers that are also analyzing BPMC, 1 agrees with Konstantinos's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Initiated at Hold and Held Target at $85 on, Thursday, August 29th, 2019


These are the ratings of the 4 analyists that currently disagree with Konstantinos


  • Andrew Berens of "Morgan Stanley" Maintained at Buy with Decreased Target to $109 on, Friday, October 11th, 2019
  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $100 on, Thursday, October 3rd, 2019
  • Dane Leone of "Raymond James" Upgraded from Hold to Buy on, Thursday, September 12th, 2019
  • Joel Beatty of "Baird" Initiated at Buy and Held Target at $120 on, Friday, July 19th, 2019
Contributing Sources